RECRUITINGOBSERVATIONAL

Prostate Cancer Genetic Risk Evaluation and Screening Study

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

About This Trial

This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.

Who May Be Eligible (Plain English)

Who May Qualify: - Men 35-74 years old - No known diagnosis of prostate cancer - Life expectancy \>10 years - Meet cohort A, B, or C criteria - Cohort A: Documented pathogenic or likely pathogenic germline genetic mutation in a prostate cancer risk gene from a CLIA-certified laboratory (ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53) - Cohort B: A strong family history suggestive of high genetic risk for prostate cancer with negative clinical genetic testing - Cohort C: Individuals who self-identify as Black American or Black Caribbean with both parents and all four grandparents of Black/African ancestry Who Should NOT Join This Trial: - Prior diagnosis or treatment of prostate cancer - Inability to undergo prostate MRI - Inability to receive MRI contrast agent Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Men 35-74 years old * No known diagnosis of prostate cancer * Life expectancy \>10 years * Meet cohort A, B, or C criteria * Cohort A: Documented pathogenic or likely pathogenic germline genetic mutation in a prostate cancer risk gene from a CLIA-certified laboratory (ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53) * Cohort B: A strong family history suggestive of high genetic risk for prostate cancer with negative clinical genetic testing * Cohort C: Individuals who self-identify as Black American or Black Caribbean with both parents and all four grandparents of Black/African ancestry Exclusion Criteria: * Prior diagnosis or treatment of prostate cancer * Inability to undergo prostate MRI * Inability to receive MRI contrast agent

Treatments Being Tested

DIAGNOSTIC_TEST

Prostate cancer screening

Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate

Locations (1)

Massachusetts General Hospital

Boston, Massachusetts, United States